Baader Bank Aktiengesellschaft’s Adaptimmune Therapeutics ADAP Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,935	Closed	-$2.21K	–	488
2025 Q2	$2.21K	Buy	+14,935	New	+$3.99K	﹤0.01%	438
2025 Q1	–	Sell	-18,095	Closed	-$8.73K	–	422
2024 Q4	$8.73K	Buy	+18,095	New	+$13.2K	﹤0.01%	370
2024 Q3	–	Sell	-10,287	Closed	-$8.17K	–	442
2024 Q2	$8.17K	Buy	+10,287	New	+$11.3K	﹤0.01%	396

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Baader Bank Aktiengesellschaft's ADAP Position: Q3 2025 in Review

Baader Bank Aktiengesellschaft sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 14,935 shares — an estimated $2.21K sold.

Baader Bank Aktiengesellschaft first reported a position in ADAP in Q2 2024 and held it in 3 quarters. The position peaked at $8.73K in Q4 2024. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

Baader Bank Aktiengesellschaft reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 14,935 Adaptimmune Therapeutics shares in Q3 2025, an estimated $2.21K.
Baader Bank Aktiengesellschaft first reported a position in Adaptimmune Therapeutics in Q2 2024 and held it in 3 quarters.
Baader Bank Aktiengesellschaft's Adaptimmune Therapeutics position peaked at $8.73K in Q4 2024.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2025, filed 6 Nov 2025.